INTRODUCTION
The existence of naturally occurring antisense RNA molecuIes has been described in prokaryotes and more recently eukaryotes (1, 2) . It is believed that these RNAs directly inhibit gene expression by hybridizing to the complementary sense sequences. Since their discovery, there has been intense interest in developing antisense nucleic acid technology for use as therapeutic agents against viruses and oncogenes.
The ability to synthetically produce antisense sequences in the form of oligonucleotides has greatly facilitated the development of antisense reagents because they can be produced in large quantities and can be designed to exacting specifications. Experiments performed with standard phosphodiester-linked antisense oligonucleotides have met with varying degrees of success (3) (4) (5) (6) . The major limitation has been the development of methods for efficient delivery of oligonucleotides into appropriate compartments of the cell. The data from such experiments indicate that short oligonucieotides are transported into the cell by an active transport mechanism and are capable 559 0740-7750/92/1100-0559506.50/0 © 1992 Plenum Publishing Corporation of inhibiting gene expression (7, 8) . The in vivo applications of phosphodiester based oligonucleotides have been disappointing due to their sensitivity to nucleases, as well as very low efficiency of transport across the cell membrane.
In an attempt to alleviate the transport and nuclease sensitivity problems, oligonucleotides with nonionic internucleotide linkages have been developed (9) . Several types of modified phosphate linkages have been generated, including phosphothioesters, phosphoaramidates, and methyl phosphonates (10) (11) (12) (13) . A significant advantage of the modified oligonucleotides is that they have an extended half-life within the cell because the modified internucleotide linkages make them highly resistant to nucleases (14, 15) . The chemically modified oligonucleotides are also nonionic molecules that may have enhanced permeability to the cell membrane (16) and may have enhanced binding activities for target sequences under physiologic conditions (17) . Extensive investigation into the use of these modified oligonucleotides as potential agents against viral infections both in vitro and in vivo has revealed them to be highly effective at specifically blocking viral replication without being toxic to cells (18) (19) (20) . Although the modified oligonucleotides have shown great potential for use as therapeutic molecules, they have not become clinically practical because of the large quantities of oligonucleotide necessary to achieve a significant reduction in gene expression and lack of specificity in terms of delivery in vivo. Currently, there are no methods to efficiently and specifically deliver large quantities of oligonucleotide to a high proportion of eukaryotic cells in vitro or in vivo.
Molecular conjugates, a soluble DNA carrier system, were initially developed as a method for targeting the transfection of genes to specific cells (21, 22) . The conjugates utilize receptor-mediated endocytotic mechanisms for delivering genes into cells. The principle behind ptasmid-based molecular conjugates is that the negatively charged DNA will electrostatically interact with positively charged polylysine to form compact structures called toroids. By covatentIy linking a specific receptor ligand, such as asialoorosomucoid or transferrin, to the polylysine to form DNA-protein complexes, it has been possible to target cell-specific surface receptors and transfect plasmid DNA into cells (23) . Recently, functional conjugates were generated to cell surface receptors for asialoorosomucoid (AsOR) and transferrin (24, 25) . Using the AsOR molecular conjugates, hepatocyte-targeted gene delivery has been studied in vivo using several different animal models, including the Watanabe heritable hyperIipidemic rabbit (26) .
In the present study, AsOR molecular conjugates were investigated as a potential delivery system for antisense oligonucleotides. The study consisted of forming DNAprotein complexes between phosphorothioate antisense oligonucleotides directed toward chloramphenicol acetyltransferase (CAT) and the AsOR-polylysine conjugates. Electron microscopy revealed that the molecular conjugates formed classic toroidal structures. The antisense molecular conjugates were then analyzed for their ability to inhibit CAT activity in stably transfected cells using indirect immunofluorescence and enzymatic assays. The data presented here demonstrate that formation of molecular conjugates with an antisense oligonucleotide provides a highly efficient delivery system for large quantities of oligonucleotide to a high proportion of target cells. The use of molecular conjugates for the delivery of oligonucleotides may thus prove to be an effective approach for the development of antisense otigonucleotides as potential therapeutic agents. Oligonucleotides, Plasmids, and Cell Lines. ixm 18-base phosphorothioate oligonucleotide with the sequence: 5'-AGT-GATTTTTTTCTCCAT-3', which is complementary to the translational initiation methionine of the CAT RNA, was synthesized. A control phosphorothioate oligonucleotide, which is complementary to the translational initiation methionine of the S-gene of hepatitis B virus, was also generated with the sequence: 5'-TGATGTGATGTTCTCCAT-3'. Both oligonucleotides were synthesized on an Applied Biosystems model 391B DNA synthesizer (DNA Synthesis Core). Fulllength oligonucleotides were purified by UV-shadowing following electrophoresis on a 15% polyacrylamide-7 M urea gel. Purified oligonucleotides were resuspended in 10 mM Tris--HC1, 1 mM EDTA, pH 7.4. 3T3 fibroblasts transduced with the cDNAs for the H1 and H2b domains of the asialoglycoprotein receptor (171 cells) were graciously provided by Drs. Michael Shia and Harvey Lodish (27) . An [125I]AsOR degradation assay was performed to document the persistent expression of functional asialoglycoprotein receptor. The cells were maintained in culture in DMEM, 10% calf serum, 1% penicillinstreptomycin at 37°C in 5% CO2. The CAT clonal cell lines were produced by transfection of 171 cells with the plasmid pRSV-CAT and pSV2his (10:1 ratio) and selected in DMEM, 10% heat-inactivated calf-serum, 1% penicillin-streptomycin, and 0.12 mM histidinol (28) . IndMdual clonal cell lines were screened for CAT enzymatic activity by enzyme assay and indirect immunofluorescence. CAT-producing cell lines were then rescreened for retention of the asialoorosomucoid receptor by molecular conjugatemediated delivery of [3-actin nuclear-targeted lac Z ([3A-ntlacZ) plasmid DNA. Evidence for the receptor-mediated transfection was provided by staining the cells for [3-galactosidase activity as previously described (29) .
MATERIALS AND METHODS

Preparation of
Generation of Molecular ConjugateOligonucteotide Complexes.
To determine the ratio of conjugate to oligonucleotide required for the formation of a soluble complex, an agarose-gel retardation assay was performed. For this assay, 100 ng of the 18-mer was end-labeled with [7-32p ]ATP (3000 Ci/mmol, NEN-DuPont) using T4 polynucleotide kinase (Boehringer-Mannhelm Biochemical). Labeled oligo (1.0 ng) was mixed with excess unlabeled oligonucleotide (99 ng) in order to perform the assay. The total amount of oligonucleotide remained constant in all samples. The oligonucleotide was mixed with increasing amounts of conjugate in the following ratios 0:1, 0.1:1, 0.5:1, i:1, 2:1, 5:1, and t0:1. The DNAconjugate suspension was incubated for 30 min at room temperature. The reaction products were then analyzed on a 1.5% agarose gel. The gel was electrophoresed at 50 V for 2 h, dried down, and exposed to film overnight (Kodak, X-OMAT XAR 5).
Deliver), of Antisense Oligonucleotides into 171-CATCells. Confluent 171-CAT cells
were split 1:10 the day prior to transfection. Four hours prior to the addition of complex, the growth media was changed to DMEM, 10% heat-inactivated calf serum (68°C, 1 h), 1% penicillin-streptomycin, and i mM CaC12 Oligonucleotide-containing complexes were formed using the following protocol: The oligonucleotide-to-conjugate ratios were varied from 0:1 to 10:1 (mass ratio). The AsOR-poly(L-lysine) conjugate was diluted to an appropriate concentration in 0.1.5 M NaC1, 20 mM HEPES, pH 7.8, in a total volume of 500 lxl. The oligonucleotide was resuspended in 10 mM Tris-HC1, 1 mM EDTA, pH 7.4. A predetermined amount of oligonucleotide was then transferred to a solution of 0.15 M NaC1, 20 mM HEPES, pH 7.8 in a final volume of 500 /,I. The oligonucleotide and conjugate preparations were then mixed together for a final volume of 1 ml, gently vortexed, incubated at room temperature for 30 min, and filtered through a 0.45 txm filter prior to its addition to the 171 cells. The complex (1 ml) was added directly to 4 ml of the DMEM, 10% heat-inactivated calf serum, 1% penicillin-streptomycin, and 1 mM CaC12 in the presence of 50 ~M chloroquine (Sigma). Cells were incubated in the presence of complex for 24 h and then analyzed for CAT activity by indirect immunofluorescence and enzyme assay of lysates.
Functionality of Oligonucleotide Molecular Conjugates.
In an attempt to examine the effectiveness of the oligonucleotide toroids, the incorporation of labeled oligonucleotide into tissue culture cells was assessed in the context of free oligonucleotide versus complexed oligonucleotide. For this analysis, 500 ng of the 18-mer oligonucleotide was end-labeled with [~-3~P]ATP (3000 Ci/mol, NEN-DuPont) using T4 polynucleotide kinase (Boehringer Mannheim Biochemical). A total of 1 x 106 cpm of purified oligonucleotide (100 ng) was mixed with excess unlabeled oligonucleotide (100 ~g) to efficiently form toroids when the DNA was mixed with conjugate at a 5:1 ratio. An equivalent amount of free oligonucleotide was prepared but not complexed to conjugate. Both 171 and 3T3 cells were split to a density of 5 x 105 cells in a 60-mm tissue culture dish in DMEM, 10% heat-inactivated calf serum, 1% penicillin-streptomycin, and i mM CaC12.
Four hours prior to the addition of oligonucleotide, the media on the cells was replaced with fresh media. The cells were then incubated with the free and complexed oligonucleotide samples over a 3-h time period with samples removed at predetermined intervals of 0, 15, 30, 60, 120, and 180 min. For each time point, the cells were trypsinized off the dish, washed twice in PBS, and then incubated with DNase (1 unit/~g) for 1 h at 37°C. The samples were then pelleted in a microfuge at 4°C for 5 min, washed three times in PBS, and finally analyzed by scintillation counting.
Chloramphenicol Acetyltransferase Assays. The net inhibition of CAT activity in the cell population was estimated by performing enzyme assays of cell lysates. The cells were washed twice in PBS, and scraped from the plate in 1 ml of TNE (0.04 M Tris HCI, pH 7.4, 1 mM EDTA, 0.15 M NaCI) and placed in microfuge tubes and stored on ice. The cells were pelleted in a microfuge for 3 min at 4°C, the supernatant aspirated, and the cell pellet frozen at -20°C. The cell pellets were resuspended in 100 ixI of 0.25 M Tris HCI, pH 7.8. The cells were frozen in a dry ice-ethanol bath for 5 min and immediately placed at 37°C for 5 rain. The freezethawing was repeated two additional times to generate the cell lysate. Protein concentration was assayed by performing a Bradford protein assay. Cell extract (20 Ixg) was assayed for CAT activity in the presence of 50 ~Ci [14C]chloramphenicol (Amersham), 0.25 M Tris HC1, pH 7.8, 0.5 mM acetyl-CoA (Pharmacia) at 37°C for 30 rain. Reactions products were extracted in 1 ml ethyl acetate, dried down in a speed-vac, resuspended in 30 txl ethyl acetate, and spotted onto thin-layer chromatography plates (Kodak, Chromagram). Chromatography was performed in chloroform-methanol (19:1, v/v). CAT assays were analyzed and quantified on a Betagen scanner.
Indirect Irnmunofluorescent Detection of CAT.
The efficiency of delivery of antisense oligonucleotides by the complexes was studied at the cellular level using a rabbit polyclonal antibody generated against CAT (5'-3'). The transfected cells were grown and transfected on glass cover slips for this analysis. After 24 h in the presence of complex, the cells were washed twice in phosphate-buffered saline (PBS) and fixed in methanol for 10 min on ice. Cover slips were subsequently washed in PBS and incubated in a 1:100 dilution of CAT antibody for 30 min at 37°C. The primary antibody was detected by incubating cells in FITCconjugated goat anti-rabbit IgG (1:200) for 30 min at 37°C. After washing in PBS, the cover slips were mounted in Citifluor mounting media (Citifluor LTD) and examined using a Microphot-FXA microscope (Nikon).
Electron Microscopy. Solutions of complex were incubated on collodion-carboncoated grids at room temperature. Excess solution was removed by capillary action and the samples were negatively stained by incubation in 2% uranyl magnesium acetate. At least two grids were examined for each complex sample using a Phillips CM-10 transmission electron microscope. All structurally defined complex macromolecules were documented by photomicrographs.
RESULTS
Binding of oligonucleotide to conjugate was assessed by a simple electrophoretic assay in which the products of the DNAprotein complex formation were electrophoresed through a nondenaturing agarose gel. Increasing amounts of conjugate (0-1 tzg) were added to a mixture of tracer 32p_ end-labeled oligonucleotide (1 ng) and unlabeled oligonucleotide (99 ng). Autoradiography of a typical experiment is presented in Fig. i . Free oligonucleotide migrates far into the gel while complexed otigonucleotide is markedly retarded. Increasing the conjugateto-oligonucleotide ratio to 5:1 leads to complete formation of complex that does not electrophorese out of the well.
In an attempt to define the structure of the resulting DNA-protein complex, the products of reactions analyzed in Fig. 1 were further characterized by electron microscopy using negative staining. Complex formed at mass ratios of conjugate-DNA less than or equal to 2:1 revealed no specific macromolecular structures. As shown in Fig. 2 , when the mass ratio of conjugate to oligonucleotide was increased to 5:1, donutlike structures with diameters ranging from 50 to 150 nm were consistently observed. Similar structures, called toroids, have been previously observed as a result of binding polycations to high-molecular-weight DNA (30) .
Functionality of the AsOR-poly(Llysine)-oligonucleotide complexes was assessed using a mouse fibroblast cell line genetically modified to stably express the asialoglycoprotein (ASGP) receptor and CAT. The cell line used in the present study is called 171. Since the 171 cells were directly derived from NIH 3T3 ceils, this provided the unique opportunity to retain a genetic control in terms of ASGP receptor expression. The role of the ASGP receptor in the mediation of uptake of molecular conjugates can be assessed by direct comparison of 171 and 3T3 cells that have been engineered to express CAT.
The effectiveness of molecular conjugates for delivery of oIigonucleotides into eukaryotic cells was assessed by monitoring uptake of free and complexed 32p endlabeled oligonucleotide. Figure 3 demonstrates the results of incorporation of free and complexed oligonucleotide into 171 and 3T3 cells. In the presence of free oligonucleotide, both cell lines showed a timedependent increase in the label associated with the cells pellet over the time period. However, when the cells are incubated in presence of oligonucleotide toroids, a timedependent incorporation of oligonucleotide was only obsel-v-ed in the 171 cells. Additionally, the amount of label associated with the cell pellet was threefold greater in the 171 cells when it was in the context of a toroid as opposed to free oligonucleotide.
The 171 cell line was exposed to increasing concentrations of oligonucleotide complexes (DNA ranging from 0 to 100 txg in complexes formed at a conjugate to oligonucleotide ratio of 5:1) for 24 h in the presence of chloroquine. The cells were analyzed for changes in expression of CAT by simultaneous assays for enzymatic activity in cell lysates and indirect immunofluorescence to detect protein at a cellular level. Figure 4A summarizes the effect of increasing concentrations of oligonucleotide complex on CAT activity in whole cell lysate. Increasing the concentration of CAT antisense oligonucleotide toroids in the media was associated with inhibition of CAT activity in the lysate to a maximum of 54 _+ 4% (mean +_ 1 SD, N >_ 3) inhibition. This inhibition was prevented when the toroids were incubated with an excess of the AsOR, indicating that it is the result of receptor-mediated uptake processes. Inhibition of CAT activity was not observed with toroids containing oligonucleotides against the S-gene region of hepatitis B virus, indicating that the effect is sequencespecific and not a nonspecific effect of toroid uptake. Incubation of 3T3-CAT cells with oligonucleotide toroids revealed no inhibition of CAT activity in cell extracts. Having demonstrated the function of antisense-containing toroids, conditions were determined to optimize their activity in vitro. Complexes formed with different ratios of conjugate and D N A were characterized with respect to inhibition of CAT activity in 171 cells (Fig. 6 ). Complexes formed with proteinto-DNA mass ratios of up to 2:1 showed insignificant levels of inhibition of CAT expression, while complexes formed at the 5:1 and 10:1 mass ratios showed a marked increase in the levels of inhibition of CAT activity.
In order to more fully understand the effectiveness of the oligonucleotide complexes as a delivery system, 171 CAT cells were incubated in the presence of increasing concentrations of naked oligonucleotides up to a maximum of 30 p.M (850 Ixg/5 ml). As shown in Fig. 7 , the level of inhibition of CAT expression is proportional to the concentration of oligonucleotide with 62 _+ 4% (mean _+ 1 SD, N >_ 3) inhibition achieved with free oligonucleotide. Analysis of these cells by indirect immunofluorescence for the CAT protein revealed a broad range of residual CAT protein, but showed only a few cells in which CAT expression was totally inhibited ( ~ 5%, data not shown).
D I S C U S S I O N
A significant problem with in vivo applications of antisense oligonucleotide technology is the difficulty associated with Antisense Oligonucleotide (gg) the naked oligonucleotides in the culture media. The oligonucleotide is transported into the cell by active transport mechanisms. The drawback of this approach is that milligram quantities of oligonucleotide are often required to observe inhibitory effects. Direct microinjection of oligonucleotides into cells has been successfully utilized to deliver large quantities of oligonucleotide to cells (31) . However, this approach is severely limited by the inability to inject oligonucleotide into a large number of cells. Lastly, liposome-mediated delivery of oligonucteotides has been used as a moderately successful nonspecific approach for delivery (32) . The method described in this report is based on the stable and nondestructive interactions of phosphorothioate oligonucteotides and the AsOR-poly(L-lysine) conjugates. Under appropriate conditions mixtures of oligonucleotide and conjugate form a stable toroidal structure easily visualized under EM. This structure resembles a donut of 50-150 nm in diameter. Our studies indicate that the toroidal structure is necessary to achieve efficient antisense delivery. The toroids formed with the oligonucleotide have the same range of diameter as those formed with plasmid DNA, indicating that there may be a standard size range for the toroids, which would provide a great deal of continuity for the use of molecular conjugates for gene delivery (data not shown).
An important factor in the use of molecular conjugates for the delivery of antisense oligonucleotides is the ability to significantly reduce gene expression with substantially less oligonucleotide. The delivery of oligonucleotides in the context of a toroid appears to be much more efficient than uptake by the active transport mechanism of free oligonucleotides, as demonstrated by the incorporation of 32P-labeled oligonucleotide in the context of a toroid. Fivefold less oligonucleotide was required to achieve 50% inhibition of CAT when it is delivered in the context of a toroid. It is also important to note that when oligonucleotides were delivered by molecular conjugates, there was a significant subpopulation of cells that lacked any detectable CAT activity. Cells incubated with noncomplexed oligonucleotide showed a reduction in CAT activity, but when examined by indirect immunofluorescence > 95% of the cells retained some levels of CAT protein. The improved delivery of oligonucleotides by molecular conjugates marks a significant improvement in the effectiveness of antisense oligonucleotides for the inhibition of gene expression.
Another significant advantage of molecular complexes is the potential for the cell-specific targeting of oligonucleotide delivery. The uptake of the AsOR-poly(L-lysine)-oligonucleotide complexes is clearly mediated by the ASGP receptor found on the 171 cells. The fact that a preselected receptor ligand is utilized in the formation of the complexes should permit them to be targeted to a specific population or subset of cells within a heterogenous population. Providing that the complexes are stable in vivo, this specificity should provide a viable approach to efficiently deliver large amounts of the oligonucleotide precisely to a selected target organ.
In this report, we summarize the development of a system for the efficient and targeted delivery of antisense oligonucleotides to eukaryotic cells. The use of molecular conjugates for the delivery of oligonucleotides may prove to be a significant advancement in the area of antisense oligonucleotide derived therapies. Experiments are currently in progress to examine the effectiveness of molecular conjugates in vivo. 
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